Current and emerging concepts in tumour metastasis

Journal of Pathology

Volumn 222, Issue 1, 2010, Pages 1-15

  Coghlin, Caroline ^a   Murray, Graeme I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cell migration; Extracellular matrix; Invasion; Matrix metalloproteinases; Metastasis; Neoplasm; Pre metastatic niche; Stem cell

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BROMODOMAIN 4; CD133 ANTIGEN; CD44V ANTIGEN; EPIDERMAL GROWTH FACTOR; MATRILYSIN; PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST METASTASIS; CANCER GROWTH; CANCER INVASION; CANCER RESEARCH; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL MIGRATION; CLINICAL PRACTICE; CLONE; COLORECTAL CANCER; DISSEMINATED CANCER; DORMANCY; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; METASTASIS; ONCOGENE K RAS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CELL MOVEMENT; DIPHOSPHONATES; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS;

EID: 77955497101     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2727     Document Type: Review

References (132)

1. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572. (Pubitemid 37328923)
3. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742-1757. (Pubitemid 46755391)
4. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008; 214: 283-293.
5. Mazzocca A, Carloni V. The metastatic process: methodological advances and pharmacological challenges. Curr Med Chem 2009; 16: 1704-1717.
6. Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-2823.
7. Curran S, Dundas SR, Buxton J, et al . Matrix metalloproteinase/ tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10: 8229-8234. (Pubitemid 40053382)
8. Coghlin C, Carpenter B, Dundas SR, et al . Characterisation and over-expression of chaperonin T-complex proteins in colorectal cancer. J Pathol 2006; 210: 351-357. (Pubitemid 44660514)
9. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461-462. (Pubitemid 26191919)
10. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133: 571-573.
11. Chen LL, Blumm N, Christakis NA, et al . Cancer metastasis networks and the prediction of progression patterns. Br J Cancer 2009; 101: 749-758.
12. Kats-Ugurlu G, Roodink I, de Weijert M, et al . Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol 2009; 219: 287-293.
13. Hart IR. New evidence for tumour embolism as a mode of metastasis. J Pathol 2009; 219: 275-276.
14. Royston D, Jackson DG. Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma. J Pathol 2009; 217: 608-619.
15. Clasper S, Royston D, Baban D, et al . A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res 2008; 68: 7293-7303.
16. Kaplan RN, Riba RD, Zacharoulis S, et al . VEGFR1-positive haematopoietic bone marrow progentitors initiate the premetastatic niche. Nature 2005; 438: 821-827.
17. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the 'premetastatic niche': within bone and beyond. Cancer Metast Rev 2006; 25: 521-529.
18. Kaplan RN, Rafii S, Lyden D. Preparing the 'soil': the premetastatic niche. Cancer Res 2006; 66: 11089-11093.
19. Bernards R, Weinberg RA. A progression puzzle. Nature 2002; 418: 823.
20. Weinberg RA. Leaving home early: re-examination of the canonical models of tumour progression. Cancer Cell 2008; 14: 283-284.
21. Klein CA. The metastatic cascade. Science 2008; 321: 1785-1787.
22. Talmadge JE. Clonal selection of metastasis within the life history of a tumor. Cancer Res 2007; 67: 11471-11475.
23. Pardal R, Clark MF, Morrison SJ. Applying the principals of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902. (Pubitemid 37500174)
24. Lapidot T, Sirard C, Vormoor J, et al . A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
25. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988. (Pubitemid 36418143)
26. Bonnet D, Dick JE. Human acute myeloid leukaemia is organised as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737. (Pubitemid 27298715)
27. Jones JR, Armstrong SA. Cancer stem cells in hematopoietic malignancies. Biol Blood Marrow Transpl. 2008; 14(suppl 1): 12-16. (Pubitemid 350286843)
28. Steven WL, Gilliland DG. Leukaemia stem cells. Semin Cancer Biol 2009; 22: 1-6.
29. O'Brien CA, Pollet A, Gallinger S, et al . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
30. Shipitsin M, Campbell LL, Argani P, et al . Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11: 69-82.
31. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers and relevance. Lab Invest 2008; 88: 459-463.
32. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med 2005; 11: 296-300.
33. Singh SK, Hawkins C, Clarke ID, et al . Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401. (Pubitemid 39551674)
34. Collins AT, Berry PA, Hyde C, et al . Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
35. - metastatic colon caner cells initiate tumors. J Clin Invest 2008; 118: 2111-2120.
36. Wu MW, Fackler MJ, Haluska MK, et al . Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008; 14: 1938-1946.
37. Vogelstein B, Fearon ER, Hamilton SR, et al . Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
38. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001; 1: 55-67. (Pubitemid 33741881)
39. Brabletz T, Jung A, Reu S, et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001; 98: 10356-10361.
40. Fodde R, Brabletz T. Wnt/β-catenin signaling in cancer stemness and malignant behaviour. Curr Opin Cell Biol 2007; 19: 150-158. (Pubitemid 46386404)
41. Brabletz T, Jung A, Spaderna S, et al . Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744-749.
42. Tsuji T, Ibaragi S, Hu G-F. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 2009; 69: 7135-7139.
43. Zipori D. The stem state: plasticity is essential, whereas selfrenewal and hierarchy are optional. Stem Cells 2005; 23: 719-726. (Pubitemid 40791787)
44. van't Veer LJ, Dai H, van de Vijver MJ, et al . Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
45. Singh D, Febbo PG, Ross K, et al . Gene expression correlates of clinical prostate cancer behaviour. Cancer Cell 2002; 1: 203-209.
46. Lui R, Wang X, Chen GY, et al . The prognostic role of a gene signature from tumorigenic breast cancer cells. N Engl J Med 2007; 356: 217-226. (Pubitemid 46143225)
47. Sorlie T, Perou CM, Tibshirani R, et al . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
48. Lifsted T, Le Voyer T, Williams M, et al . Identification of inbred mouse strains harboring genetic modifiers of mammary tumour age of onset and metastatic progression. Int J Cancer 1998; 77: 640-644. (Pubitemid 28340915)
49. McBride G. Breast cancer metastasis: do variations in inherited genes make a difference. J Natl Cancer Inst 2008; 100: 768-769.
50. Crawford NP, Ziogas A, Peel DJ, et al . Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006; 8: R16. (Pubitemid 44377915)
51. Crawford NP, Alsarraj J, Lukes L, et al . Bromodomain 4 activation predicts cancer survival. Proc Natl Acad Sci USA 2008; 105: 6380-6385.
52. Hüsemann Y, Geigl JB, Schubert F, et al . Systemic spread in early breast cancer. Cancer Cell 2008; 13: 58-68.
53. Klein CA. The systemic progression of human cancer: a focus on the individual disseminated cancer cell-the unit of selection. Adv Cancer Res 2003; 89: 35-67.
54. Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 2008; 14: 5013-5021.
55. Klein CA, Stoecklein NH. Lessons from an aggressive cancer: evolutionary dynamics in esophageal cancer. Cancer Res 2009; 69: 5285-5288.
56. Stoecklein NH, Hosch SB, Bezler M, et al . Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008; 13: 441-453.
57. Schmidt-Kittler O, Rag T, Daskalakis A, et al . From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 7737-7742.
58. Podyspanina K, Yi-Chieh ND, Jechlinger M, et al . Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008; 321: 1841-1844.
59. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904. (Pubitemid 44175140)
60. Yang J, Mani SA, Weinberg AW. Exploring a new twist on tumor metastasis. Cancer Res 2006; 66: 4549-4552.
61. Yang J, Mani SA, Donaher JL, et al . Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.
62. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740-746.
63. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14: 818-829. (Pubitemid 351757205)
64. Rinker-Schaeffer CW, O'Keefe JP, Welch DR, et al . Metastasis suppressor proteins: discovery, molecular mechanisms and clinical application. Clin Cancer Res 2006; 12: 3882-3889.
65. Rosivatz E, Becker I, Specht K, et al . Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1 and twist in gastric cancer. Am J Pathol 2002; 161: 1881-1891.
66. Hoek K, Rimm DL, Williams KR, et al . Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004; 64: 5270-5282.
67. Ansieau S, Bastid J, Doreau A, et al . Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008; 14: 79-89.
68. Weinberg RA. Twisted epithelial-mesenchymal transition blocks senescence. Nat Cell Biol 2008; 10: 1021-1023.
69. Luzzi JK, MacDonald IC, Schmidt EE, et al . Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early metastases. Am J Pathol 1998; 153: 865-873.
70. Wels J, Kaplan RN, Rafii S, et al . Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 2008; 22: 559-574. (Pubitemid 351342429)
71. Erler JT, Bennewith KL, Nicolau M, et al . Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-1226.
72. Erler JT, Giaccia AJ. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res 2006; 66: 10238-10241.
73. Erler JT, Bennewith KL, Cox TR, et al . Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15: 35-44.
74. Müller A, Homey B, Soto H, et al . Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
75. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
76. Fidler IJ, Kim S-J, Langley RR. The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 2007; 101: 927-936. (Pubitemid 47040873)
77. Geiger TR, Peeper DS. Metastatic mechanisms. Biochem Biophys Acta 2009; 1796: 293-308.
78. Nguyen DX, Bos PD, Masssgue J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
79. Kuhn NZ, Tuan RS. Regulation of stemness and stem niche of mesenchymal stem cells: implications in tumourigenesis and metastasis. J Cell Physiol 2010; 222: 268-277.
80. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9: 285-293.
81. Hedley BD, Chambers AF. Tumor dormancy and metastasis. Adv Cancer Res 2009; 102: 67-101.
82. McGowan PM, Kirstein JM, Chambers AF. Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncol 2009; 5: 1083-1098.
83. Mareel M, Maria JO, Madani I. Cancer invasion and metastasis: interacting ecosystems. Virchows Arch 2009; 454: 599-622.
84. Bidard F-C, Pierga J-Y, Vincent-Salomon A, et al. A 'class action' against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metast Rev 2008; 27: 5-10.
85. Giampieri S, Manning C, Hooper S, et al . Localized and reversible TGF-β signalling switches breast cancer cells from cohesive to single cells motility. Nat Cell Biol 2009; 11: 1287-1296.
86. Thiery JP. Metastasis: alone or together? Curr Biol 2009; 19: R1121-1123.
87. Kirfel G, Rigort A, Borm B, et al . Cell migration: mechanisms of rear detachment and formation of migration tracks. Eur J Cell Biol 2004; 83: 717-724.
88. Auguste P, Fallavollita L, Wang N, et al . The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 2007; 170: 1781-1792.
89. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007; 67: 5064-5066.
90. Mantovani A, Allavena P, Sica A, et al . Cancer-related inflammation. Nature 2008; 454: 436-444.
91. Colotta F, Allavena P, Sica A, et al . Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
92. Mantovani A. Inflaming metastasis. Nature 2009; 457: 36-37.
93. +) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer 2009; 125: 879-886.
94. Stout RD, Watkins SK, Suttles J. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol 2009; 86: 1105-1109.
95. Dong C, Robertson GP. Immunoediting of leukocyte functions within tumor microenvironment promotes cancer metastasis development. Biorheology 2009; 46: 265-279.
96. Wu Y, Deng J, Rychahou PG, et al . Stabilization of snail by NF-κB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009; 15: 416-428.
97. Pardoll D. Metastasis-promoting immunity: when T cells turn to the dark side. Cancer Cell 2009; 16: 81-82.
98. Solinas G, Germano G, Mantovani A, et al . Tumor-associated macrophages (TAM) as major players of cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-73.
99. VanSaun MN, Lee IK, Washington MK, et al . High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol 2009; 175: 355-364.
100. Wu Y, Brodt P, Sun H, et al . Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res 2010; 70: 57-67.
101. Gao D, Mittal V. The role of bone-marrow derived cells in tumor growth, metastasis initiation and progression. Trends Mol Med 2009; 15: 333-343.
102. + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
103. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008; 84: 623-630.
104. Robinson BD, Sica GL, Lui YF, et al . Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 2009; 15: 2433-2441.
105. Wyckoff JB, Wang Y, Lin EY, et al . Direct visualisation of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007; 67: 2649-2656. (Pubitemid 46548952)
106. Sleeman JP, Thiele W. Tumor metastasis and the lymphatic vasculature. Int J Cancer 2009; 125: 2747-2756.
107. Zhang Q, Yang M, Shen J, et al . The role of the intravascular microenvironment in spontaneous metastasis development. Int J Cancer 2010; 126: 2534-2541.
108. Sakuma Y, Takeuchi T, Nakamura Y, et al . Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. J Pathol 2010; 220: 574-585.
109. Jeffery N, McLean MH, El-Omar EM, et al . The matrix metalloproteinase/ tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Histopathology 2009; 54: 820-828.
110. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133: 994-1005.
111. Coleman RE. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 2009; 45: 1909-1915.
112. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9(suppl 4): 14-27.
113. Buijs JT, Que I, Löwik CW, et al . Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009; 44: 380-386.
114. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009; 310: 71-81.
115. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
116. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005; 18(328): 679-687.
117. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treatment Rev 2008; 34: 453-475.
118. Verdijk R, Franke HR, Wolbers F. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007; 247: 308-312.
119. Brown HK, Holen I. Anti-tumour effects of bisphosphonates - what have we learned from in vivo models? Curr Cancer Drug Targets 2009; 9: 807-823.
120. Tang X, Zhang Q, Shi S, et al . Bisphosphonates suppress insulinlike growth factor 1-induced angiogenesis via the HIF-1α/VEGF signaling pathways in human breast cancer cells. Int J Cancer 2010; 126: 90-103.
121. Santini D, Vincenzi B, Avvisati G, et al . Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2002; 8: 1080-1084. (Pubitemid 34517643)
122. Ottewell PD, Woodward JK, Lefley DV, et al . Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009; 8: 2821-2832.
123. Woodward J, Coleman RE, Holen I. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs 2005; 16: 11-19.
124. Gnant M, Mlineritsch B, Schippinger W, et al . Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
125. Gnant M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 2009; 9: 824-833.
126. Winter MC, Thorpe HC, Burkinshaw R, et al . The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct antitumor activity in breast cancer. Cancer Res 2009; 69(suppl 2): 330S.
127. Winter MC, Coleman RE. Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol 2009; 21: 499-506.
128. Bedard PL, Body JJ, Piccart-Gebhart MJ. Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer. J Clin Oncol 2009; 27: 4043-4046.
129. Solomayer E, Gebauer G, Hirnle P, et al . Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res 2009; 69(suppl 2): 171S.
130. Dearnaley DP, Mason MD, Parmar MK, et al . Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009; 10: 872-876.
131. Welch DR, Cooper CR, Hurst DR, et al . Metastasis Research Society-American Association for Cancer Research Joint Conference on Metastasis. Cancer Res 2008; 68: 9578-9582.
132. Nash KT, Phadke PA, Navenot J-M, et al . KISS1 metastasis suppressor secretion, multiple organ metastasis suppression and maintenance of tumour dormancy. J Natl Cancer Inst 2007; 99: 309-321.